PURPOSE: Despite a high cure rate in patients with testicular cancer, there remain patients in the poor prognosis group who have a less favorable outcome. Intensive induction chemotherapy using a regimen consisting of carboplatin, bleomycin, vincristine, and cisplatin, followed by bleomycin, etoposide, and cisplatin (CBOP/BEP), developed at the Royal Marsden Hospital, is designed to overcome the rapid proliferation seen in germ cell tumors. This study assesses the outcome of patients with poor-prognosis nonseminomatous germ cell tumors (NSGCT) treated with CBOP/BEP. PATIENTS AND METHODS: Patients with NSGCT from three centers, classified as poor prognosis according to International Germ Cell Classification Consensus Group criteria, were treated with CBOP/BEP regimen during the period from 1989 to 2000. Data on treatment toxicity, relapse-free survival (RFS), and overall survival (OS) were collected prospectively on a hospital database. RESULTS: Fifty-four male patients with poor prognosis NSGCT were treated with CBOP/BEP. The RFS at 3 and 5 years for all patients was 83.2% (95% confidence interval [CI], 68.8% to 91.3%). After a median follow-up of 4 years, the OS of the 54 patients was 91.5% (95% CI, 78.6% to 96.8%) at 3 years and 87.6% (95% CI, 71.3% to 94.9%) at 5 years. Three-year OS in patients with a primary mediastinal germ cell tumor was 77.1% (95% CI, 34.5% to 93.9%) compared with 95.4% (95% CI, 82.8% to 98.8%) in patients with a testicular primary tumor (P =.24). CONCLUSION: The results reported here compare favorably with the historical results of alternative regimens used in the management of poor-prognosis NSGCT. We suggest a phase III trial to confirm our findings.
PURPOSE: Despite a high cure rate in patients with testicular cancer, there remain patients in the poor prognosis group who have a less favorable outcome. Intensive induction chemotherapy using a regimen consisting of carboplatin, bleomycin, vincristine, and cisplatin, followed by bleomycin, etoposide, and cisplatin (CBOP/BEP), developed at the Royal Marsden Hospital, is designed to overcome the rapid proliferation seen in germ cell tumors. This study assesses the outcome of patients with poor-prognosis nonseminomatous germ cell tumors (NSGCT) treated with CBOP/BEP. PATIENTS AND METHODS: Patients with NSGCT from three centers, classified as poor prognosis according to International Germ Cell Classification Consensus Group criteria, were treated with CBOP/BEP regimen during the period from 1989 to 2000. Data on treatment toxicity, relapse-free survival (RFS), and overall survival (OS) were collected prospectively on a hospital database. RESULTS: Fifty-four male patients with poor prognosis NSGCT were treated with CBOP/BEP. The RFS at 3 and 5 years for all patients was 83.2% (95% confidence interval [CI], 68.8% to 91.3%). After a median follow-up of 4 years, the OS of the 54 patients was 91.5% (95% CI, 78.6% to 96.8%) at 3 years and 87.6% (95% CI, 71.3% to 94.9%) at 5 years. Three-year OS in patients with a primary mediastinal germ cell tumor was 77.1% (95% CI, 34.5% to 93.9%) compared with 95.4% (95% CI, 82.8% to 98.8%) in patients with a testicular primary tumor (P =.24). CONCLUSION: The results reported here compare favorably with the historical results of alternative regimens used in the management of poor-prognosis NSGCT. We suggest a phase III trial to confirm our findings.
Authors: Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann Journal: Drugs Date: 2006 Impact factor: 9.546
Authors: Y Rimmer; J Chester; J Joffe; D Stark; J Shamash; T Powles; J White; J Wason; D Parashar; G Armstrong; D Mazhar; M V Williams Journal: Br J Cancer Date: 2011-08-16 Impact factor: 7.640
Authors: D P Dearnaley; S D Fossa; S B Kaye; M H Cullen; S J Harland; M P J Sokal; J D Graham; J T Roberts; G M Mead; M V Williams; P A Cook; S P Stenning Journal: Br J Cancer Date: 2005-06-20 Impact factor: 7.640
Authors: S D Fosså; B Paluchowska; A Horwich; G Kaiser; P H M de Mulder; O Koriakine; A T van Oosterom; L de Prijck; L Collette; R de Wit Journal: Br J Cancer Date: 2005-11-28 Impact factor: 7.640
Authors: Sara J Stoneham; Juliet P Hale; Carlos Rodriguez-Galindo; Ha Dang; Thomas Olson; Matthew Murray; James F Amatruda; Claire Thornton; G Suren Arul; Deborah Billmire; Mark Krailo; Dan Stark; Al Covens; Jean Hurteau; Sally Stenning; James C Nicholson; David Gershenson; A Lindsay Frazier Journal: Oncologist Date: 2014-06-04
Authors: D A Anthoney; M J McKean; J T Roberts; A W Hutcheon; J Graham; W Jones; J Paul; S B Kaye Journal: Br J Cancer Date: 2004-02-09 Impact factor: 7.640
Authors: J Shamash; T Powles; W Ansell; Dan Berney; J Stebbing; K Mutsvangwa; P Wilson; S Asterling; S Liu; P Wyatt; S P Joel; R T D Oliver Journal: Br J Cancer Date: 2007-07-03 Impact factor: 7.640